| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ALC1; chd1l; CHDL;;CHD1L |
| WB Predicted band size | 101 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human CHD1L |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇与CHD1L抗体相关的文献示例(文献信息为模拟概括，实际引用请核实原文)：
1. **文献名称**：CHD1L promotes hepatocellular carcinoma progression and metastasis in mice
**作者**：Ma NF et al.
**摘要**：研究使用CHD1L特异性抗体(如Abcam货号abxxxx)通过免疫组化分析肝癌组织，证实CHD1L过表达与肿瘤转移和患者预后不良相关，并揭示其通过调控EMT通路促进侵袭的机制。
2. **文献名称**：Oncogenic role of CHD1L in pancreatic cancer
**作者**：Chen L et al.
**摘要**：通过Western blot(使用CST公司CHD1L抗体#xxxx)和免疫荧光技术，发现CHD1L在胰腺癌中异常高表达，并通过稳定β-catenin蛋白增强肿瘤细胞增殖，提示其作为治疗靶点的潜力。
3. **文献名称**：CHD1L interacts with PARP1 to promote DNA repair in ovarian cancer
**作者**：Wang Y et al.
**摘要**：利用CHD1L抗体(Proteintech货号xxxxx)进行Co-IP实验，揭示CHD1L与PARP1的相互作用，证明其通过同源重组修复途径参与卵巢癌化疗耐药，为联合靶向治疗提供依据。
---
**注**：以上内容为示例，实际文献需通过PubMed或Google Scholar以“CHD1L antibody”或“CHD1L function”等关键词检索，建议优先选择近5年、高影响因子的研究。部分经典文献可能侧重CHD1L功能而非抗体应用细节。
The CHD1L (Chromodomain Helicase DNA-Binding Protein 1-Like) antibody is a tool used to detect and study the CHD1L protein, a member of the SNF2-like helicase family involved in chromatin remodeling and DNA repair. CHD1L, located on chromosome 1q21. is implicated in transcriptional regulation, genome stability, and carcinogenesis. Its overexpression has been linked to tumor progression, particularly in hepatocellular carcinoma (HCC), where it promotes cell proliferation, metastasis, and chemoresistance by modulating pathways like Wnt/β-catenin and PI3K/Akt.
CHD1L antibodies are essential for investigating its biological roles, including its interaction with PARP1 in DNA damage repair and its oncogenic potential. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess CHD1L expression levels in clinical samples or experimental models. Elevated CHD1L levels are associated with poor prognosis in multiple cancers, making it a potential biomarker for diagnosis and therapeutic targeting.
Research using CHD1L antibodies has also explored its role in developmental processes and stem cell regulation. Commercially available antibodies are validated for specificity and sensitivity, though variability between clones requires careful experimental optimization. Continued studies aim to clarify CHD1L's molecular mechanisms and its utility in precision oncology.
×
